October 24, 2024

Axovia Therapeutics and Rhythm Pharmaceuticals Announce Joint Research Collaboration in Bardet-Biedl Syndrome

July 11, 2024

Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer

May 2, 2024

Epsilogen appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as part of broader company expansion

May 1, 2024

Alek Safarian shares his opinions on the current funding environment for biotech, and introduces ALSA Ventures and its investment philosophy.

October 24, 2023

Oxford BioTherapeutics announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers

October 3, 2023

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

September 18, 2023

ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd

July 31, 2023

Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer

July 19, 2023

ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease

October 19, 2022

Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro.

October 3, 2022

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

June 13, 2022

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

May 27, 2022

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

May 25, 2022

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT’s Antibody Drug Conjugate OBT076 in combination with Agenus CPI Balstilimab

May 9, 2022

Lonza and ALSA Ventures Collaborate to Provide Development and Manufacturing Services for Biotech Firms

April 13, 2022

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

April 7, 2022

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

March 22, 2022

BioNeex and ALSA Ventures Partner to Provide Biotech Firms a New Way to Drug Candidate Out-Licensing and Acquiring Investment

March 2, 2022

Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing

September 20, 2021

Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic

June 14, 2021

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics

March 31, 2021

Montis Biosciences appoints René Hoet as Chief Scientific Officer

March 8, 2021

ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer

February 16, 2021

Nature Article Cites IgE Antibodies as a Technology to Watch in 2021 and Notes their Potential as an Anti-Cancer Therapy

January 19, 2021

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

January 6, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

November 9, 2020

Epsilogen Announces Formation of Clinical Advisory Board

October 22, 2020

ALSA Ventures webinar: Investing in biotechnology in the COVID era

October 14, 2020

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

October 12, 2020

ALSA Ventures Launches European Biotech Clinical Accelerator ‘Eclipse’ to speed preclinical assets into the clinic

October 12, 2020

Featured on EurekAlert!

ALSA Ventures launches European biotech clinical accelerator 'Eclipse'

September 29, 2020

Dr. Karen Zinkewich-Péotti brings brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech

September 22, 2020

Featured on Endpoints News

Ex-CRO boss scores veteran VCs and $59M for his Euro-focused fund

September 16, 2020

ALSA Ventures today announced first closing of its European biotechnology investment fund with commitments of US$59M

July 20, 2020

Epsilogen announces further UK government funding to develop next generation antibody treatments for ovarian cancer

June 30, 2020

ALSA Ventures Webinar: European Biotech Investments for Family Offices

April 27, 2020

Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting

April 20, 2020

Interim phase 1 data evaluating MOv18 IgE, an anti-folate receptor alpha IgE antibody, in cancer patients with advanced solid tumours to be presented at the AACR Virtual Annual Meeting I

April 20, 2020

Epsilogen licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London

March 31, 2020

Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim Collaboration

February 20, 2020

Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology

January 9, 2020

Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors

August 27, 2019

IGEM Therapeutics announces final close of £5 million Series A financing round